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large and growing number of new therapeutic
compounds aiming at “disease modification” in
Alzheimer’s disease (AD) are currently under clinical
investigation (Table I). However, these innovative ther-
apeutic approaches require a variety of novel biomark-
ers with differentiated roles and functions to ensure
objectivity and efficiency of drug development, as well
as the initiation and monitoring of drug treatment in
patients. Accordingly, new guideline documents from
regulatory authorities, such as the FDA and EMEA, will
most likely strongly recommend thorough validation of
biological, as well as imaging, candidate markers as pri-
mary end points in upcoming phase II and III treatment
trials of compounds claiming disease-modifying proper-
ties. In this context, the ideal biomarker would serve at
least two purposes. 
￿ First, it would enable early diagnosis, which also relates
to early detection of pathophysiology. This is particu-
larly important for “disease modification” and early
intervention in a condition that progresses for 5 to 8
years prior to awareness of cognitive loss.
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The introduction of biological markers in the clinical
management of Alzheimer’s disease (AD) will not only
improve diagnosis relating to early detection of neu-
ropathology with underlying molecular mechanisms, but
also provides tools for the assessment of objective treat-
ment benefits. In this review, we identify a number of in
vivo neurochemistry and neuroimaging techniques,
which can reliably assess aspects of physiology, pathol-
ogy, chemistry, and neuroanatomy of AD, and hold
promise as meaningful biomarkers in the early diagnos-
tic process, as well as for the tracking of disease-modify-
ing pharmacological effects. These neurobiological mea-
sures appear to relate closely to pathophysiological,
neuropathological, and clinical data, such as hyperphos-
phorylation of tau, abeta metabolism, lipid peroxidation,
pattern and rate of atrophy, loss of neuronal integrity,
and functional and cognitive decline, as well as risk of
future decline. As a perspective, the important role of
biomarkers in the development of innovative drug treat-
ments for AD and the related regulatory process is dis-
cussed. 
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Translational research￿ Secondly, the biomarker would enable assessment of
objective treatment benefit so that the therapeutic reg-
imen could be adjusted according to patient response.
Those biomarkers could also serve as objective end
points in clinical trials assessing the efficacy of new
compounds.
Large-scale, controlled, multicenter biomarker trials are
currently being conducted in US, Japanese, Australian,
and European Alzheimer networks (Alzheimer’s
Disease Neuroimaging Initiative, ie, US-ADNI and E-
ADNI) in an attempt to systematically develop and val-
idate core feasible candidate biomarkers in research
areas such as neurochemistry and structural and func-
tional imaging.
To date, a large and increasing number of monocenter
studies and an increasing number of more or less con-
trolled multicenter trials have investigated biomarker
candidates for AD. Potential diagnostic biomarkers are
measured against the criteria established by expert con-
sensus conferences.
1,2These guidelines specify that a bio-
marker should reflect a neuropathological characteris-
tic of AD and should be validated in patients with a
neuropathological diagnosis. The sensitivity of the
“ideal” biomarker to detect AD should be at least 85%.
Its specificity to differentiate AD patients from controls
of the same age and from patients with other forms of
dementia should be at least 75%. In clinically diagnosed
populations, a higher level of specificity for biomarkers
will not be able to be achieved for methodological rea-
sons, as even the gold standard, the clinical diagnostic
criteria, cannot be absolutely specific. The same applies
to controls of the same age, as some of them might have
undetected incipient preclinical AD.
3 In large groups, this
will inevitably affect the specificity of the results of even
the best mechanistic biomarker.
In contrast to early detection of pathology, application
of biomarkers to map treatment effects is still at an early
stage. An overview of the current literature provides an
initial indication that treatment effects may indeed be
reflected at the biomarker level. However, results are
still inconclusive. In several cases, biomarker studies
have led to unexpected results that opened up new ques-
tions; the answers to these questions will probably
enhance our understanding of the pathophysiology of
AD in the future. Further studies on core candidate
markers will probably show that some presumed patho-
mechanisms of marker regulation and expression are
more differentiated and complex than currently sup-
posed.
This paper will present an overview of the most promis-
ing findings relating to biomarkers which can be
assessed in vivo. A particular focus will be on biomark-
ers that have already been evaluated on clinical samples
(eg, using structural and functional imaging methods or
analysis of cerebrospinal fluid and plasma/serum). At the
end of the article, a short discussion on the regulatory
and industrial perspective of the topic will also be pro-
vided.
Biomarkers derived from neuroimaging
Structural magnetic resonance imaging 
(morphometry)
Hippocampus volumetry
High-resolution magnetic resonance imaging (MRI)
determines structural changes in the brain in vivo.
Significant atrophy of the hippocampal formation,
entorhinal cortex, and parahippocampal gyrus can be
demonstrated by MRI, even in the preclinical stages of
AD, and predict later conversion to AD with about 80%
accuracy.
4-6 Manual volumetric methods are currently the
gold standard to determine the hippocampal volume, but
they are time-intensive.
7 Hippocampal volumetry is the
best-established structural biomarker for AD, particu-
larly for early diagnosis, and appears to be suitable for
risk stratification in mild cognitive impairment (MCI)
cohorts in treatment trials. Controlled multicenter diag-
nostic studies are currently being conducted on manual
hippocampal volumetry within the German Dementia
Network to establish whether this method would be reli-
able and accurate for broader clinical application.
8
However, the procedure is still time-consuming and
involves a great deal of manual work, and therefore is
not set to become a routine diagnostic test in the fore-
seeable future.
Several studies have focussed on the temporal rate of
change of hippocampal atrophy in AD patients. Atrophy
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Selected abbreviations and acronyms
AD Alzheimer's disease
MCI mild cognitive impairment
MRI magnetic resonance imaging
MRS magnetic resonance spectroscopy
PET positron emission tomography
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Table I. Potential disease-modifying and amyloid-targeting agents in development. Sources: a, www.clinicaltrials.gov; b, www.neurochem.com; c,
www.lilly.com; d, www.cornell.edu; e, www.phrma.org; f, www.regentherapeutics.com; g, www.affiris.com
Assessment
Brain-scanning techniques 
(FDG-PET, vMRI, AV-45-PET); 
biochemical measures; 
ADAS-Cog, CDR, MMSE; 
NPI; Qol-AD; RUD-Lite; 
EQ-5D Proxy
Pharmacokinetic analysis; 
safety assessments including 
vital signs; physical exam; 
symptom checklist; complete 
blood count; serum chemistries; 
urinalysis; electrocardiogram; 
ADAS-Cog
Biomarkers amyloid beta 40 
and 42 in CSF
Cognitive and functional 
measures
Physical/neurological 
examination; ECG; vital signs; 
standard and special 
immunological laboratory 
evaluations; MRI; EEG; AE/SAE 
monitoring; IgM and IgM titers 
against amyloid and carrier 
protein
Other outcomes
Determine levels of peptides in 
blood and spinal fluid that might 
relate to Alzheimer's disease; 
evaluate changes in thinking and 
memory; evaluate changes in 
daily living activities; determine 
levels of study drug in blood 
and CSF
Clinician's Global Impression of 
Change (ADCS-CGIC); Mini-
Mental Status Exam (MMSE); 
Activities of daily living (ADCS-
ADL); neuropsychiatric inventory; 
insulin sensitivity and secretion; 
biomarkers; ApoE genotyping
Pharmacodynamics and 
pharmacokinetics
Pharmacokinetics as evaluated 
from the blood and urine 
concentrations of GSI-136; 
pharmacodynamics as evaluated 
from the levels of select 
biomarkers in the blood and the 
administration of a visual analog 
scale to measure sedation effects
Immunogenicity of each dose 
level of ACC-001 with or without 
QS-21 in subjects with mild to 
moderate AD
Immune response; cognitive and 
functional assessments
Immunogenicity
Immunological and clinical 
efficacy (evaluated in an 
explorative manner)
Immunological and clinical
efficacy (evaluated in an
explorative manner)
Primary outcomes
Safety and tolerability; 
rate of cognitive and 
functional decline in 
AD over time
Pharmacokinetics; safety
Safety
Safety and tolerability
Safety and tolerability
Tolerability and safety 
assessments; 
antibody titers
General safety and 
tolerability
Tolerability
Tolerability
Study Follow-up
γ-secretase LY-450139 21 months
inhibitor/ (Eli Lilly, 
modulator Phase III)
a,c,e
NIC5-15 7 weeks
(Humanetics, 
Phase II)
a
GSI-953 (begacestat) 10 months
(Wyeth, Phase I)
a
GSI-136 6 months
(Wyeth, Phase I)
a
Immuno- ACC-001 24 months
therapy  (Élan/Wyeth, Phase III)
a,e
(Active)
CAD-106 52 weeks
(Novartis/Cytos, Phase II)
a
V950 4 years
(Merck, Phase I)
a
Affitope AD01 12 months
(Affiris, Phase I)
a,g
Affitope AD02 12 months
(Affiris, Phase I)
a,g144
Table I. Continued
Assessment
Adverse events; vital signs; 
physical exam; neuro exam; 
12-lead ECG; lab tests 
(hematology, blood chemistry, 
urinalysis); MRI
Vital signs; Weight; Clinical 
laboratory tests; 
electrocardiograms [ECGs]; 
brain magnetic resonance 
imaging [MRIs]; physical and 
neurological examinations; 
infusion site assessments
ADAS-Cog; ADCS-CGIC; 3MS; 
ADCS-ADL; NPI; GDS; QOL; 
ADCS; pharmacoeconomic 
assessment; plasma and CSF 
anti-amyloid antibody titers; 
plasma and CSF beta amyloid 
levels; FDG cerebral glucose 
utilization; PIB cerebral amyloid 
distribution (PET); PK11195 
microglial activation (PET); 
adverse event frequency 
and severity
Physical and neurological 
examination; brain MRI; 
cognitive status; laboratory 
parameters; ECG; vital signs
AEs; 
Laboratory parameters; 
vital signs
Other outcomes
Effects of PF 04494700 on 
potential biomarkers of RAGE 
inhibition and amyloid imaging 
(AV-45, F18 PET); potential dose 
response of PF 04494700; 
Pharmacokinetics and 
pharmacodynamics
Blood levels of administered 
study drug; cognitive and 
functional assessments
Activities of daily living, 
behavior, and quality of life
To determine the plasma 
pharmacokinetics of LY2062430; 
to evaluate the pharmacokinetic/ 
pharmacodynamic relationships 
between LY2062430 
concentrations and plasma 
peptide amyloid beta 
concentrations; to evaluate the 
changes in thinking and memory
Pharmacokinetic parameters; 
pharmacodynamic effects; 
effect on plasma and CSF 
biomarkers; titre and neutralizing
activity of antibodies
CSF biomarkers; 
clinical efficacy parameters
Primary outcomes
Efficacy; safety and 
tolerability
Safety assessments
Cognition and global 
function
Adverse events
Safety; tolerability; 
immunogenicity
Safety; tolerability; 
pharmacokinetics in 
plasma; 
pharmacodynamics
Study Follow-up
PF-04494700 18 months
(Pfizer, Phase I)
a
Immuno- NIC5-15 24 months
therapy AAB-001  
(Passive) (bapineuzumab)
(Élan/Wyeth,
Phase II)
a
Gammagard (IvIG) 18 months
(Baxter/Cornell, 
Phase III)
a,d
LY-2062430 6  months
(solanezumab)
(Eli Lilly, Phase II)
a
GSK933776A 52 weeks
(GSK, Phase I)
a
R1450 24 months
(Roche, Phase I)
a
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rates of 3% to 7% per annum were demonstrated,
9-11
while healthy controls show a maximum atrophy rate of
0.9% in old age.
12 Hippocampal volume is thus a core
candidate structural progression marker of AD. The hip-
pocampus volumetry method is already being used as a
secondary end point in several pharmacological trials.
There are indications that volumetric markers might be
approved as surrogate end points and primary outcome
variables in trials on drugs claiming disease modification
by regulatory authorities such as the FDA and EMEA
in the future.
The application of hippocampal volumetry might be fur-
ther improved in the short term by implementing semi-
automated and fully automated analysis procedures.
Automated methods which have a good correlation with
manual measurements and reduce the measurement
time from 2 h to 30 min are now becoming available.
13,14
However, the automated protocols of hippocampal vol-
umetry in AD patients still need to be comprehensively
validated. 
Volumetry of the entorhinal cortex
Another very promising anatomical structure for the
early diagnosis of AD is the entorhinal cortex, which lies
adjacent to the hippocampus. This area is hypothesized
to be affected by the neurodegenerative process at a
particularly early stage. Studies have shown that entorhi-
nal cortex volumetry is unlikely to provide any addi-
tional benefit in patients with manifest AD
15-18; however,
at the MCI stage, it may gradually improve prognostic
efficiency by a few percent compared with hippocampal
volumetry.
16,19 However, it should be reflected that
entorhinal cortex volumetry is even considerably more
laborious than hippocampal volumetry, and that no
automated procedures are available for this structure
yet. Sufficient data have not yet been obtained to assess
whether entorhinal cortex volume does indeed offer an
additional benefit over hippocampal volume as a surro-
gate end point to evaluate the efficiency of a particular
treatment. 
Automated data-driven neuroimaging methods
Due to the laborious nature of initial manual volumet-
ric methods, various automated methods have been
developed over the past years to demonstrate change in
brain structure and morphology in AD patients more
efficiently, and in some cases using hypothesis- and rater-
independent approaches. One of the best-established
methods is the automated measurement of the whole
brain volume over time, which is already being used as
a secondary end point in clinical treatment trials. This
method demonstrated an atrophy rate of approximately
2.5% whole brain volume reduction in AD patients over
the course of 1 year, compared with only 0.4% to 0.9%
in healthy controls. However, the heuristic value of this
method is limited, as only global effects can be recorded
without providing information about regionally differ-
entiated effects. 
Voxel-based volumetry 
The most commonly investigated method to date is
voxel-based volumetry (VBM),
20 which consistently
shows a reduction in the cortical gray matter in the
Table I. Continued
Assessment
ADAS-Cog.; CDR, MRI
ADAS-Cog; CGIC; IADL; MMSE; 
Global Deterioration Scale; 
Geriatric Depression Scale; 
ADAS-Non Cog; gradation 
of overall patient response
Other outcomes
Brain volume change from 
baseline as measured by MRI
Cognition (memory, 
language, reasoning); 
function (activities of 
daily living)
Primary outcomes
Safety, efficacy and 
disease-modifying 
potential
Safety and tolerability; 
cognitive and 
functional measures
Efficacy; 
tolerability
Study Follow-up
Aggregation Tramiprosate 18 months
Inhibitor (3APS)
(Neurochem, Phase III)
a,b
(Pfizer, Phase I)
a
AZD103 18 months
(Élan/Transition, 
Phase II)
a,e
ColostrininTM (O-CLN) 30 weeks
(ReGen Therapeutics, 
Phase II)
fregion of the mediotemporal lobes and lateral temporal
and parietal association areas in AD patients.
21,22 In MCI
subjects, involvement of the mediotemporal lobe and lat-
eral association areas of the temporal and parietal lobes
was demonstrated using VBM.
23,24 Interestingly, signifi-
cant atrophy of mediotemporal, laterotemporal, and
parietal association areas was observed in a genetic risk
model, even years before clinical symptoms were man-
ifested, indicating preclinical neurodegeneration in the
neocortical association areas.
25,26 This adds to the com-
monly used neuropathological staging model, which
hypothesizes primarily early preclinical mediotemporal
changes. One study demonstrated a considerably differ-
ent pattern of cortical atrophy between patients with
MCI who went on to develop AD in the subsequent clin-
ical course and those whose cognitive performance
remained stable.
27 The patients who converted to AD
showed a pattern of atrophy that was largely consistent
with that of early AD.
28 However, VBM offers no direct
way of making an individual diagnosis as it is always
based on group statistics. 
Deformation-based morphometry 
While VBM transforms brain images into a standard
space, thus compensating for global differences in the
position of the head and the size of the brain, but pre-
serving local differences in the distribution of the corti-
cal gray matter that can then be used as a basis for
detecting group differences, deformation-based mor-
phometry (DBM) transforms the brain volumes at high
resolution to a standard template brain, thus completely
eliminating the anatomical differences between the
brains. The anatomic information then is no longer
found in the MRI images themselves, but instead in the
deformation fields that are required to transform the
patient’s brain into a standard brain. These deformation
fields offer a multivariate vector field of localization
information, from which regional volume effects can be
extrapolated.
In a recent study using multivariate principal component
analysis, DBM was used to calculate an individual risk
for the presence of AD in MCI subjects. This method
allowed a group separation of about 80% between AD
patients and healthy controls. Interestingly, the accuracy
in distinguishing between MCI subjects who developed
dementia over a period of 1
1/2 years, and MCI subjects
whose cognitive performance remained stable over time
was 70% to 80%. This method may thus be used for indi-
vidual risk prediction.
29 It has yet to be applied more
extensively to a larger number of MRI scans. 
Analysis of cortical thickness
Another interesting automated method involves deter-
mining the cortical thickness of the neocortical associ-
ation areas and the entorhinal cortex.
30 Group separa-
tion showed an accuracy of more than 90% in
distinguishing between AD patients and healthy con-
trols.
31 However, this method has yet to be evaluated in
an independent group, and the accuracy of this method
in predicting conversion to AD in MCI subjects has not
yet been studied. 
Imaging the cholinergic nuclei in the basal forebrain
The imaging of structural changes in the region of the
cholinergic nuclei of the basal forebrain was recently
established using a combination of automated methods
with regional information. The cholinergic projections
from the basal forebrain to the cortex are affected early
on in AD. An MRI-based method showed a signal
reduction in the region of the lateral and medial nuclei
of the basal nucleus of Meynert for the first time in
vivo.
32-34
Functional magnetic resonance imaging (fMRI)
The utilization of functional magnetic resonance imag-
ing (fMRI) allows for the measurement of brain activa-
tion during cognitive tasks at a high level of resolution
without any radiation exposure to the patient. There
have been many studies that have examined brain acti-
vation changes in MCI subjects compared with AD, for
the development of a marker of early AD.
35-37 One new
approach has been to investigate changes in the func-
tional connectivity between regions of an activated net-
work.
38 Functional connectivity gives a measure of the
linear association between two regions and is a function
of the phase relationship between the regions’ signals.
39
An investigation of functional connectivity in MCI sub-
jects have shown that there are widespread changes in
functional connectivity of the fusiform gyrus to other
visual processing areas, and areas within the ventral and
dorsal visual pathways.
38The changes in functional con-
nectivity preceded differences in brain activation
146
Translational researchbetween the MCI and healthy control group. Given that
cognitive function requires a high level of integration
across the network subserving cognitive function, it sug-
gests that the first factor that may be altered in the brain
by the putative AD neuropathology is the integration
across a neural network. In addition, it has been found
that the activation level within the fusiform gyrus was
more strongly correlated to the gray matter density in
the ventral and dorsal visual pathways compared with
the healthy controls, further suggesting that changes in
the entire network affect activation within a network
region.
40 A study of working memory in AD patients
41
provides further evidence that cognitive decline in AD
is due to a breakdown in the integrated activity of a net-
work. When subjects performed a working memory task,
the functional connectivity between the frontal lobe and
the hippocampus was disrupted in the AD patients and
they recruited a different network that included the
amygdala, prefrontal regions, and anterior and posterior
cingulated gyrus to perform the task. The activation in
the frontal lobes of the healthy controls showed strong
correlation with posterior cortical areas, while in the AD
patients the frontal lobe activity was primarily correlated
with other frontal regions. In a follow-up study with
semantic and episodic memory task, it was shown that
the different network in the AD patients represents a
compensatory mechanism as the activity in the network
was correlated with memory performance.
42
Recent work also suggests that cognitive performance is
not only a function of a single network, but that the inter-
action between networks plays a role in cognition.
43 In an
associative memory task performed by mild AD patients,
MCI subjects, and healthy controls, it was shown that acti-
vation of the hippocampus and deactivation of medial and
lateral parietal regions was reciprocal.
35The hippocampus
was part of a network that included regions in the occipi-
tal-temporal lobes and frontal lobes while the deactivation
in the parietal regions was part of the default network
44
that includes the posterior cingulate and medial frontal
lobe regions. The activation in the memory network and
the deactivation in the default network were linearly cor-
related, providing evidence that the activation dynamics
in the two networks are directly connected. The level of
deactivation of the default network during a cognitive task
differed among healthy controls, MCI patients, and AD
patients.
45
Investigation of the default network measured during
fixation (no task) has shown altered functional connec-
tivity between the left and right hippocampus to the rest
of the brain in AD patients compared with healthy con-
trols.
46 This raises the possibility of utilizing the default
network to quantify the functional impairment in the
brain without using a cognitive task. In particular, Wang
and colleagues found that the functional connectivity
between the hippocampus and visual cortices was
impaired, further supporting the results of impaired
functional connectivity found during a visual matching
task in MCI patients. In addition, the functional connec-
tivity between the hippocampus and posterior cingulate
are strongly disrupted in AD patients.
36
The network connectivity also can be investigated using
diffusion tensor imaging (DTI), which provides a mea-
sure of the structural integrity of the white matter tracts
connecting regions of the brain.
47 Recent application of
DTI with AD patients has found decreases in the struc-
tural integrity of the white matter tracts in the corpus
callosum, cingulum, and fornix, and frontal, temporal,
and occipital lobe white matter areas.
40,48-50 The integra-
tion of fMRI with DTI to investigate changes across a
neural network has the potential to be a very powerful
tool to aid in the development of a marker for AD.
However, previous studies assessing the potential of
fMRI changes to serve as a marker for early pathology
and for potential treatment effects in AD are still in a
pilot stage including only small samples. Results need to
be replicated in larger samples using prospective and
longitudinal study designs.
Magnetic resonance spectroscopy
One common finding reported in the magnetic reso-
nance spectroscopy (MRS) literature as associated with
AD is a decrease in N-acetyl-aspartate concentration
(NAA) and its ratio to creatine (Cr).
51-54A positive cor-
relation between NAA, and NAA/Cr, and Mini Mental
State Examination (MMSE) scores in neurodegenera-
tive disorders has also been reported.
55 NAA is a free
amino acid, present in the brain at relatively high con-
centrations (8 to 12 mM/kg wet weight). Its function is
poorly understood, but it is believed to act as an osmo-
lite, a storage form of aspartate, and a precursor of N-
acetyl-aspartate-glutamate. Given that NAA is predom-
inantly intraneuronal, it has been widely used as a
marker of neuronal density.
56 Observations suggesting
that disruption of mitochondrial energy metabolism
leads to a reversible drop in NAA,
57 however, lead to the
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neuronal dysfunction rather than neuronal loss. 
A second finding reported in the literature as associated
with AD is an increase in the myo-Inositol (mI) concen-
tration, as well as its ratio to creatine.
54,58,59 mI is a cyclic
sugar alcohol, whose role in the brain is not well under-
stood. It is generally believed that mI is an essential
requirement for cell growth, an osmolite, and a storage
form for glucose.
60 It has also been proposed as a glial
cell marker. Normal concentrations of mI range from 4
to 8 mmol/kg wet weight. 
Given the importance of developing surrogate markers
for AD diagnosis, ways to improve the performance of
MRS-based methods have been proposed. The use of
metabolite tailored pulse sequences
61,62 has been pro-
posed for AD diagnosis and treatment. Such pulse
sequences are optimized for measurement of some
metabolites (eg, NAA and mI) while degrading perfor-
mance for acquisition of data from others. Although
improvements in data acquisition and quantification
protocols are bound to significantly reduce measure-
ment variability for MRS data, it is unlikely that such
methods will ever acquire the sensitivity and specificity
needed to diagnose or monitor treatment in AD on an
individual patient basis. The limited chemical shift range
for proton MRS (~5 ppm) leads to the existence of a
very narrow range for chemical signatures of hundreds
of aminoacids and chemical compounds found in human
brains. In practice, only a limited number of them (of the
order of 10), characterized by large concentrations (>1
mM) and favorable spectral signatures, can be accurately
measured in vivo in a clinical setting. This fact can lead
to reduced specificity, as many neurological diseases or
disease stages can be characterized by similar changes in
the concentrations of the metabolites that can be mea-
sured accurately. Secondly, MRS measurements per-
formed in vivo can never become more repeatable than
measurements performed in phantoms; for most
metabolites, measurement repeatability in vitro is lim-
ited to 2% to 3%. Consequently, assuming that this limit
is reached in vivo, changes on the order of ~5% in
metabolite concentrations will be needed on an individ-
ual patient basis, in order for this change to be attributed
to changes due to disease or treatment. Unfortunately,
natural variability of baseline states of different persons
is within this range, preventing diagnosis of the disease
using this approach. Moreover, such small changes from
the baseline state of one person might require more than
a few weeks of drug treatment, if trying to decide whether
a treatment works or not. On the upside, however, MRS
measurements are short, noninvasive, and can easily
yield quantitative results with commercially available
data analysis programs.
63 Such MRS-based approaches
for monitoring disease response to treatment can prove
invaluable for phase II clinical trials, by allowing a sig-
nificant reduction of the number of enrolees.
51,64
Positron emission tomography
Positron emission tomography (PET) using 
18fluo-
rodeoxyglucose (18FDG) is used to study cortical
metabolism. In AD patients, 18FDG-PET shows a typ-
ical pattern of reduced cortical uptake in the region of
the temporal and parietal association cortex, particularly
in the region of the posterior cingulum; in mild-to-mod-
erate stages of AD, prefrontal association areas are
affected as well.
65
MCI subjects already show—to a lesser extent—a sim-
ilar distribution of metabolic deficits which can predict
conversion from MCI to AD with an accuracy of over
80%.
66,67 Many researchers regard 18FDG-PET as the
gold standard in the in vivo diagnosis of early stages of
AD, although this method is not widely available and is
relatively expensive. The benefit of 18FDG-PET for dif-
ferential diagnosis in AD patients is less well validated.
Established automated analysis algorithms are already
available for PET investigations, providing clinicians
with z-score maps for metabolic deviation (for example
see ref 68). PET has not yet been used in multicenter
treatment trials; however, several monocenter studies
have been conducted with PET demonstrating the effect
of cholinergic treatment, in particular, on the metabolic
pattern in AD patients. A problematic aspect of the
majority of the studies is that the analyses are usually
based on unblinded treatment arms and that treated
responders (according to clinical criteria) were com-
pared with untreated and treated nonresponders.
69 A
double-blind study comparing verum- and placebo-
treated patients regardless of the clinical effects showed
a significant effect of treatment with a cholinesterase
inhibitor on cortical metabolism and on the cortical acti-
vation.
70 The extent of these effects, however, was con-
siderably smaller than in the previous studies.
A promising approach in PET involves imaging the recep-
tor binding of specific transmitters. By administering
positron emitters of labelled receptor agonists or antago-
148
Translational researchnists, quantitative measures can be obtained on specific
transmitter binding and its kinetics on the basis of biophys-
ical models. Compared with healthy controls, this method
can be used to indicate reduced or upregulated receptor
expression. In recent years, markers of the muscarinergic
system have been developed that demonstrate specific
reductions in binding in AD patients, but they have not yet
been sufficiently evaluated to allow diagnostic statements
to be made.
71A further interesting marker is the imaging
of acetylcholinesterase activity.
72 In one study, a significant
effect of treatment with a cholinesterase inhibitor was
shown on the expression of acetylcholinesterase in the cor-
tex.
73 Here, sufficient data are not yet available as well to
assess the method’s potential for diagnostic use or its value
as a secondary end point as part of a treatment trial. 
Novel markers have recently been developed to image
amyloid plaques using PET in AD patients. The most
extensively studied radiotracer is Pittsburgh Compound B
(PIB), which shows a specifically enhanced uptake in AD
patients compared with healthy controls.
74 It is not clear at
present, however, whether the diagnostic accuracy of this
method may be better than that of the more matured
FDG-PET. However, its application in treatment studies
to investigate amyloid-modifying strategies as a marker of
a biological mechanism would be conceivable.
Biomarkers derived from neurochemical CSF analysis
Amyloid beta peptides
The discovery that amyloid beta peptide forms the main
component of AD plaques primarily with a length of 42
amino acids (Aβ42)
75 and that it is secreted by cells
76 led
to investigations of Aβ42 in the cerebrospinal fluid
(CSF). Around 20 studies have been conducted on some
2000 patients and controls showing a reduction of Aβ42
by about 50% in AD patients compared with nonde-
mented controls of the same age; the diagnostic sensitiv-
ity and specificity levels range between 80% and 90%.
77
In healthy subjects, the concentration exceeds 500 pg/mL
in all age groups.
78 It is not clear why Aβ42 is reduced in
AD patients. Compared with other types of dementia,
the specificity level is only approximately 60%.
79 An
autopsy study demonstrated an inverse correlation
between Aβ42 levels in the CSF and the number of
plaques,
80 and it was recently shown that subjects with a
positive signal in amyloid positron emission tomography
(PET) studies using Pittsburgh Compound B (PIB; see
below) had the lowest Aβ42 values in the CSF.
81 Future
studies need to take account of the considerable diurnal
fluctuations in Aβ levels in the CSF.
82
Total tau protein (t-tau)
The main component relating to intraneuronal changes
in AD patients is the microtubule-associated tau protein.
Abnormal aggregates can only be formed if the tau pro-
tein is released from its sites of binding.
83 In AD patients,
tau protein is present in a pathological, hyperphospho-
rylated form. Incidentally, tau pathology can also be
observed in other neurodegenerative diseases, but dif-
fers from tau pathology in AD patients at the molecular
level.
84Tau protein was quantified in the CSF under the
hypothesis that it is released extracellularly as a result of
the neurodegenerative process. The methods initially
available analyzed all forms of tau regardless of their
phosphorylation status at specific epitopes, ie, total tau
protein (t-tau).
Around 50 studies have been conducted to date with
some 5000 patients and controls, and have all demon-
strated an increase in the concentration of t-tau in AD
patients by approximately 300% compared with nonde-
mented elderly subjects, and a systematic increase in the
concentration with age was observed in the control
groups.
85,86 The sensitivity and specificity levels were
between 80% and 90% for t-tau as well.
77 In subjects
younger than 50 years, the concentrations in the CSF are
usually lower than 300 pg/mL, in subjects younger than
70 years lower than 450 pg/mL, and in the over 70s lower
than 500 pg/mL.
78 Both t-tau and Aβ42 were already sig-
nificantly altered in subjects with mild cognitive impair-
ment (MCI) who are at increased risk of AD over time.
87
Although the AD group could be differentiated from
healthy controls of the same age—with a sensitivity of
85% and a specificity of 86%—using a combination of
the two markers, the differential diagnosis (classifica-
tion) between AD and other primary degenerative
dementias was unsatisfactory (sensitivity = 85%, speci-
ficity = 58%).
79 Therefore, more specific biomarkers
were sought.
Hyperphosphorylated tau protein (p-tau)
Approximately 30 phosphorylation epitopes have been
detected in AD. Around 1999, the first methods were
published and demonstrated concentrations of hyper-
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studies to date have investigated tau protein hyperphos-
phorylated at threonine 231 (p-tau231P) and at threo-
nine 181 (p-tau181P), and a few results have been
obtained for serine 199 (p-tau199P). A correlation with
neurofibrillary neocortical pathology was demonstrated
for p-tau231P in the CSF,
88 but not for p-tau181P.
89 Single
studies are available on other epitopes as well.
An increase in p-tau has consistently been found in the
CSF of AD patients compared with controls. Around 20
studies have been conducted on some 2000 patients and
controls with sensitivity and specificity levels of between
80% and 90%. Differences have certainly been observed
between the individual p-tau subtypes in distinguishing
between the groups. P-tau231P and p-tau181P show bet-
ter results than p-tau199P in distinguishing AD from
control groups and even from other types of dementia.
90
These and other studies suggest that p-tau is promising
in distinguishing AD from frontotemporal dementia
(FTD), with sensitivity and specificity rates of 85% to
90%.
90,91A combination of various p-tau subtypes did not
provide improved results in distinguishing between the
groups due to ceiling effects. P-tau may also be useful in
distinguishing AD from idiopathic normal pressure
hydrocephalus (iNPH). A study found similarly altered
concentrations of t-tau and Aβ42 in both groups com-
pared with controls, while p-tau181P was considerably
higher in the AD group only.
92The sensitivity and speci-
ficity rates were higher than 85%. A systematic review
discusses what clinical benefit p-tau might offer. The
high negative predictive value of p-tau of approximately
90% appears to be particularly significant. This means
that normal values rule out the presence of AD with
almost 90% probability.
93
In MCI subjects, high p-tau231P concentrations corre-
lated with a decline in cognitive performance and con-
version to AD.
94 Similar results were established for p-
tau181P.
95 The three p-tau subtypes presented above
were comparable in this respect.
96 High p-tau231P con-
centrations at the initial examination also correlated
with structural disease progression, measured as the rate
of hippocampal atrophy in the course of the disease.
97A
recent European multicenter trial on CSF p-tau231 in
MCI subjects has shown that the results for p-tau in pre-
dicting AD in this risk group are indeed stable and con-
sistent throughout multiple centers. In this study p-tau
proved to be a powerful candidate predictor of AD in
MCI subjects even in a very short mean observation
interval of only 1 to 2 years.
98 This result is particularly
promising regarding clinical use of p-tau by general
practitioners or consultants in order to inform patients
as early as possible.
A Swedish 6-year study investigated the predictive value
of the combined t-tau, Aβ42, and p-tau181P (defined as
a ratio) for AD in a group of 137 MCI patients.
99AD was
able to be predicted in the MCI subjects with a sensitiv-
ity of 95% and a specificity of approximately 85%, both
with a combination of t-tau and Aβ42 and with a combi-
nation of t-tau and the ratio of Aβ42/p-tau181P.
99 This
suggests that a useful combination of markers may opti-
mize prediction in a more heterogenous MCI population
over a longer observation period.
The single assay methods have been modified by using
the Luminex xMAP® technology (Luminex Corp,
Austin, TX) based on flow cytometry, which allows sev-
eral parameters to be determined at the same time; the
three biomarker candidates presented here can thus be
measured at once using a relatively small volume of CSF.
The first multicenter results are promising.
100
Determination of these parameters is implemented both
in the US and the European dementia networks. The
first round-robin study is currently being conducted.
Novel and emerging approaches
A particularly promising new approach in the CSF
focuses on the detection and quantification of β-secre-
tase (BACE-1), one of the key enzymes responsible for
the pathological amyloidogenic cleavage of the amyloid
precursor protein (APP). A significant increase was
found in BACE-1 concentration and activity in the CSF
of MCI subjects compared with healthy controls; sub-
jects with the ApoE ε4 risk allele were found to have the
highest concentrations. BACE-1 may have added value
in early detection, prediction, and biological activity of
AD.
101
Isoprostanes are also being studied as candidate mark-
ers of lipid peroxidation. An increase was found in the
CSF of MCI subjects compared with controls, and levels
also increased over time. With regards to their diagnos-
tic precision, the CSF markers isoprostanes and p-tau
performed better than memory tests. The isoprostanes
even improved the results obtained using hippocampal
volumetry to distinguish between the groups.
102
However, due to the very demanding analysis method,
isoprostanes should still be regarded as a merely scien-
150
Translational researchtific approach. This also holds true for the role of apop-
tosis, oxidative stress, and mitochondrial dysfunction in
lymphocytes as potential biomarkers for Alzheimer’s
disease which are currently under investigation.
103
Biomarkers derived from plasma and serum
The efforts to discover and develop diagnostic biomark-
ers for AD in peripheral blood, plasma, or serum has to
date not led to any core feasible candidate markers that
are even close to the diagnostic accuracy achieved by
CSF biomarkers. The best-studied candidate biomarker
in plasma so far is Aβ, but the findings are contradictory.
Some groups have reported high concentrations in
plasma of either Aβ42 or Aβ40 in AD, although with a
broad overlap between patients and controls, whereas
most groups find no change.
104 Some studies have also
reported high plasma Aβ42 (but not Aβ40) in nonde-
mented elderly people who later developed either pro-
gressive cognitive decline or AD.
105,106 Contrary to these
data, van Oijen and colleagues recently reported an asso-
ciation between high Aβ40, low Aβ42, and risk of demen-
tia,
107 a result that is in general agreement with the find-
ings of Graff-Radford and colleagues,
108 who observed a
weak association between low plasma Aβ42/Aβ40 ratio
and risk of future MCI or AD in a healthy, elderly popu-
lation. Apart from disease-related factors, the opposing
results may be due to the fact that Aβ42 is methodolog-
ically difficult to measure reliably in plasma. The peptide
is very hydrophobic and binds, not only to certain test
tube walls, but also to several plasma proteins, including
albumin, α2-macroglobulin, lipoproteins, and comple-
ment factors.
109Additionally, it is unclear what effect Aβ
oligomerization has on Aβ concentrations in plasma
measured by immunochemical assays. Both homo- and
heterotypic protein interactions could mask Aβ epitopes,
resulting in the measurement of only a fraction of Aβ.
110
This possible confounder might differ between different
methods, which could explain some of the contradictory
results in the literature. It is still unclear as well whether
the disturbed metabolism of Aβ42 in the AD brain is
reflected by changes in the levels of A‚ markers in
plasma. In fact, Aβ is produced by many different cells in
the body and there seems to be no correlation between
the levels of Aβ42 in plasma and CSF.
111,112 Similarly, other
investigations have shown that plasma Aβ42 and Aβ40
do not reflect Aβ accumulation in the brains of individ-
uals with AD.
81,113
Combination of biomarkers
It would seem obvious to combine a specific set of dif-
ferent neurochemical markers or neurochemical mark-
ers together with imaging parameters to achieve a more
accurate early and differential diagnosis and to compare
the validity of the individual methods. In agreement with
this view, combined measurements of the CSF t-tau,
Aβ42, and p-tau profile, and regional cerebral blood
flow
114 or mediotemporal lobe atrophy
115 demonstrate
higher predictive power than either diagnostic approach
alone in MCI studies. 
Particular combinations or ratios of biomarkers may be
useful in answering specific questions; in other words,
patterns or rates of change at the neurochemical level
may ultimately prove to be optimal. Thus, group separa-
tion between AD and vascular dementia patients seems
promising using the ratio of Aβ42 and p-tau.
116AD could
be distinguished from dementia with Lewy bodies
(DLB) using the ratios of Aβ peptides of varying lengths
(Aβ42/Aβ38 and Aβ42/Aβ37) and tau protein.
117 There
are also indications that the ratios of various Aβ pep-
tides improve the neurochemical profile for potential
diagnostic applications.
118,119 A combination of amyloid
imaging using PIB-PET and t-tau, Aβ peptides, p-tau
and potentially BACE-1 in the CSF has been proposed
as a possible way to improve imaging of the underlying
neuropathology and to cross-evaluate the neurochemi-
cal markers.
120These approaches are currently being pur-
sued.
The regulatory perspective
The use of biomarkers as end points in earlier stages of
drug development is well established for regulators, and
there are examples to approve medicinal products on
the basis of their effects on validated surrogate markers,
eg, antihypertensives, or cholesterol-lowering products.
121
However, these examples have been considered as vali-
dated surrogate markers as they allow substitution for a
clinically relevant end point. In their validation a link
between a treatment-induced change in the biomarker
and long-term outcome of the relevant clinical measure
was undoubtedly established. 
Unfortunately, in AD none of the imaging or neurochem-
ical markers can be considered to be sufficiently vali-
dated as a fully developed surrogate end point, thereby
making their use as primary outcome measures in pivotal
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151efficacy trials unlikely at this time. Nevertheless, they are
already utilized in ways that allow decision-making on
further drug development, they can be used as primary
prespecified outcome measures in phase II studies (proof
of concept, dose-finding) or to better define patient pop-
ulations at risk (enriched populations likely to respond
to therapy) for efficacy trials. In particular, the better def-
inition of homogeneous patient populations with AD
may permit clinical studies to be shorter or smaller in size
even in phase II, and ultimately, if any of these biomark-
ers would be found to be acceptable later on as surrogate
end points, definitive efficacy trials may also be consid-
erably shorter and/or smaller than studies using more tra-
ditional clinical outcomes. 
To validate a biomarker with regard to a possible claim
of disease modification of AD, we would look for the
link between a treatment-induced change in the neu-
roimaging or neurochemical biomarker and the desired
clinical outcome measure and the link between the treat-
ment-induced change in the neuroimaging or neuro-
chemical biomarker and change of the underlying dis-
ease process.
121 Additionally, there should be a high
plausibility that based on the assumed mechanism of
action of a given medicinal product the disease process
will be modified (based on, eg, preclinical models).
However, if the biomarkers are not fully validated, it is
very unlikely that approval will be granted on such
unvalidated surrogates as sole primary outcomes, but
benefit-risk assessment will be based on classical clini-
cal outcome trials of reasonable size and duration. 
Why are regulators so strict on validation of biomarkers?
The reliance on the pharmacological effect on a surro-
gate that has not been adequately validated (that is, for
which there has not been shown a strong correlation
between the expected change in the surrogate and a ben-
eficial effect of the drug) is troubled with interpretive
uncertainties,
122,123 eg, it is assumed that an efficacious
treatment of AD will slow the progression of medial tem-
poral lobe atrophy measured by MRI. However, in the
vaccine trial with AN1792 the extent of brain atrophy
increased in patients with antibody response and clinical
improvement.
124This outcome was surprising, and pro-
vides evidence that the effects of a treatment (even,
potentially, a beneficial treatment) on a chosen surrogate
marker can be unpredictable. Of more concern, though,
are those (potential) cases in which the desired effect on
the surrogate is achieved. If the clinical effects are
unknown, concluding that the drug has a beneficial effect
for the patients would be based on the assumption that
the desired effect seen on the surrogate will translate into
the desired beneficial clinical effect. This assumption may
be quite wrong, resulting in the approval of a treatment
that has no beneficial (or even, perhaps, a deleterious)
effect on the patient.
Nevertheless, regulatory bodies like the FDA and EMEA
have identified development of biomarkers as high prior-
ity in general and particularly in dementia.
125,126
Neurochemical and neuroimaging biomarkers are consid-
ered useful in refinement of diagnostic criteria of AD—
and possibly earlier diagnosis—as well as rendering the
natural course of disease. To foster innovation in this field
extensive collaboration of the different stakeholders is
proactively supported by regulators and hopefully will lead
to further improvement in qualification and validation of
a least some of the biomarkers towards surrogacy in AD.
Discussion
There are a number of criteria for a biomarker to qual-
ify as a useful tool in the early detection and for the
monitoring of treatment effects in AD. It needs to have
face validity, ie, measure something known to be
involved directly in the pathophysiology. It also needs to
be detectable early in the disease process; to be quantifi-
able by an automated method; and to possess a dynamic
range relevant to progression in the “natural course” of
disease as well as regression due to therapeutic interven-
tion, with sufficiently low variance to measure changes
that are small relative to rates of progression or regres-
sion. In clinical trials of drug candidates, such biomark-
ers would enable enrichment of populations, confirma-
tion of mechanisms of action (MoA), choice of dosing
regimen (“dose-ranging”), quantification of treatment
benefit, and dose titration to maximize benefit with least
risk of adverse events. The enrichment of populations in
clinical trials is particularly important due to the long
delay in onset of symptoms and the low annual rate of
conversion from MCI to mild AD. Because AD pro-
gresses slowly and treatment effects may only be mani-
fest as a slowing or halting of progression, precise mea-
surement of small changes is crucial to the design of
clinical protocols with reasonable durations of therapy
and achievable numbers of patients. Similar factors
apply to diagnostic biomarkers being developed for
direct patient care. The ability to diagnose AD patho-
physiology prior to onset of symptoms will enable ear-
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efficacy and has retained maximum cognitive perfor-
mance. In addition to their direct clinical benefit for AD
patients and caregivers, early-disease biomarkers are
also of interest to payers and purchasers of health care.
Results of such a diagnostic test can serve as a baseline
to quantify treatment benefit by longitudinal compar-
isons pre- and post-treatment. This will enable individu-
alization of the treatment regimen, leading to optimal
outcomes on a per-patient basis. Optimizing outcomes
for individuals enables efficient delivery of health care,
which in turn frees up resources to broaden access to the
latest technology. The projected costs of AD in the US
attendant upon aging of the baby boomers are astro-
nomical; it is the development of novel therapeutics and
biomarkers, or diagnostics, based on innovative technol-
ogy, which offers hope to individuals and to society.
In this review, we identified a number of in vivo neuro-
chemistry and neuroimaging techniques, which can reli-
ably assess aspects of physiology, pathology, chemistry,
and neuroanatomy of AD and hold promise as meaning-
ful biomarkers in the early diagnostic process as well as
for the tracking of disease modifying pharmacological
effects. These neurobiological measures appear to relate
closely to pathophysiological, neuropathological, and
clinical data, such as hyperphosphorylation of tau, abeta
metabolism, lipid peroxidation, pattern and rate of atro-
phy, loss of neuronal integrity, functional and cognitive
decline, as well as risk of future decline. On the neuro-
chemical level, CSF concentration of Aβ42, tau, and P-
tau can distinguish subjects with MCI who are likely to
progress to AD. They also show preclinical alterations
that predict later development of early AD symptoms.
Studies on plasma Aβ are not entirely consistent, but
recent findings suggest that decreased plasma Aβ42 rel-
ative to Aβ40 may increase the risk of AD. Increased
production of Aβ in aging is suggested by elevation of
BACE-1 protein and enzyme activity in the brain and
CSF of subjects with MCI. CSF tau and P-tau are
increased in MCI as well, and show predictive value.
Other biomarkers may indicate components of a cas-
cade initiated by Aβ, such as oxidative stress or inflam-
mation. Other interesting novel marker candidates
derived from blood are being currently proposed (phase
I). These merit further study in MCI and earlier stages.
Manual hippocampal volumetry is currently the best-
established biomarker for AD in the field of structural
imaging, but due to the laborious nature of the proce-
dure it will only be used in clinical studies for risk strat-
ification of study populations and as an end point for
treatment effects in the foreseeable future. Automated
data-driven and rater-independent methods are cur-
rently being investigated to detect regional changes,
namely VBM, DBM, and the measurement of cortical
thickness. In the medium term, particularly in combina-
tion with multivariate statistical analysis methods, analy-
sis algorithms are likely to be identified that are at least
as effective as hippocampal volumetry in the early detec-
tion of AD in MCI subjects and will therefore be used
in pharmacological studies. However, if secondary pre-
ventive treatment approaches are approved in the com-
ing years, the use of these kinds of automated methods
for the early detection of AD will be of socioeconomic
importance in routine diagnostic practice as well.
Besides structural neuroimaging, pilot studies using
other neuroimaging approaches such as PET (FDG and
PIB), DTI and MRS yielded promising results and
should be prospectively applied to larger samples.
Apart from hippocampal volumetry, whole-brain vol-
umetry is currently being investigated as a secondary
end point in several clinical studies, and other studies are
beginning on whole brain volumetry; however, the valid-
ity of this marker is limited. PET has been used as an
end point in single-center studies.
70Tau protein has also
been used as a secondary end point in clinical studies. In
an immunization study, discontinued due to serious side
effects, a reduction in t-tau in the CSF was observed in
the group of antibody responders (development of a
defined high antibody titer after vaccination) compared
with the placebo group.
127 Interestingly, MRI showed a
decrease in whole brain volume in the responder group
in this study.
124 Amyloid reduction with consecutive
changes in the CSF space is being discussed as a cause,
although this interpretation is controversial. Changes in
the concentrations of the Aβ peptides in the CSF and
plasma were reported after administration of a γ-secre-
tase inhibitor, a potential drug that may modify amyloid
pathology.
2 Furthermore, various combinations of neu-
rochemical and neuroimaging biomarkers are currently
used in several ongoing clinical trials on substances with
potential disease-modifying properties (Table I). 
Conclusions and perspectives
A number of neuroimaging candidate markers are
promising, such as hippocampus and entorhinal cortex
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153volumes, basal forebrain nuclei, cortical thickness, defor-
mation and voxel-based morphometry, structural and
effective connectivity using DTI, tractography, and
fMRI. CSF Aβ42, BACE-1, total tau, and P-tau are sub-
stantially altered in MCI and clinical AD. Biomarker dis-
covery through proteomic approaches requires further
research. Despite the large number of promising results,
biological markers of AD are at various stages of devel-
opment and clinical evaluation (referred to as develop-
ment stage I-IV), and have so far not generally been
established in clinical routine. In order to approach this
goal, large-scale international controlled multicenter tri-
als (such as the US, European, Australian, and Japanese
ADNI, and the German Dementia Network) are
engaged in phase III development of the core feasible
imaging and CSF biomarker candidates in AD. Also, bio-
markers are in the process of implementation as primary
outcome variables into regulatory guideline documents
regarding study design and approval for compounds
claiming disease modification. Specific medium-term
tasks in biomarker research include validation of the
markers in autopsy-confirmed patient groups, determi-
nation of the benefit of biomarkers in the risk stratifica-
tion of clinical study populations using medico-economic
models, and the controlled application of biomarkers in
primary care. The aim should be to have early diagnos-
tic markers ready in clinical practice when disease-mod-
ifying treatments become available so that those patients
who would benefit from these strategies can be identi-
fied and treated in time. 
To this end, there is a need for thorough and rigorous
codevelopment of biological marker candidates with
various functions and roles during all stages of drug
development. This can only be achieved through
planned synergistic collaboration between academic and
industrial research partners. Biomarker research in neu-
rodegenerative disorders is a fascinating and fast-devel-
oping area; however, much can still be learned by more
matured interdisciplinary fields, such as oncology,
immunology, and cardiovascular research. ❏
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Marcadores biológicos para la detección y el
tratamiento precoz de la Enfermedad de
Alzheimer
La introducción de marcadores biológicos en el manejo
clínico de la Enfermedad de Alzheimer (EA) no sólo mejo-
rará el diagnóstico relacionado con la detección precoz
de la neuropatología y los mecanismos moleculares sub-
yacentes, sino que también proveerá herramientas para
la evaluación de los beneficios objetivos del tratamiento.
En esta revisión se identifican varias técnicas neuroquími-
cas y de neuroimágenes in vivo, que pueden evaluar de
manera confiable aspectos fisiológicos, patológicos, quí-
micos y neuroanatómicos de la EA y se destacan prome-
tedores biomarcadores significativos en los procesos del
diagnóstico precoz, como también para el monitoreo de
los efectos farmacológicos que van modificando la enfer-
medad. Las mediciones neurobiológicas parecen relacio-
narse estrechamente con datos fisiopatológicos, neuro-
patológicos y clínicos, tales como la hiperfosforilación de
tau, el metabolismo beta-amiloide, la peroxidación de
lípidos, los patrones y frecuencias de la atrofia, la pérdida
de la integridad neuronal, y la declinación cognitiva y
funcional, como también el riesgo de futuros deterioros.
Con una visión a futuro se discute el importante papel de
los biomarcadores en el desarrollo de innovadoras tera-
pias farmacológicas para la EA y los procesos relaciona-
dos con las agencias reguladoras. 
Marqueurs biologiques de détection et  
traitement précoces de la maladie
d’Alzheimer
L’introduction des marqueurs biologiques dans la prise
en charge clinique de la maladie d’Alzheimer (MA)
devrait non seulement améliorer le diagnostic grâce à
une détection précoce de la neuropathologie et de ses
mécanismes moléculaires sous-jacents, mais également
fournir des outils pour l’évaluation des bénéfices objec-
tifs du traitement. Nous individualisons dans cet article
un certain nombre de techniques de neurochimie et de
neuro-imagerie in vivo, qui permettent d’évaluer de
façon fiable les aspects physiologiques, pathologiques,
chimiques et neuroanatomiques de la MA et qui sem-
blent prometteuses comme biomarqueurs du diagnostic
précoce, et comme outils de surveillance des effets phar-
macologiques modifiant la maladie. Ces mesures neuro-
biologiques sont étroitement liées aux données cliniques,
neuropathologiques et physiopathologiques, telles que
l’hyperphosphorylation de tau, le métabolisme de abêta,
la peroxydation lipidique, le modèle et le taux d’atrophie,
la perte d’intégrité neuronale et d’autonomie et
l’altération cognitive ainsi que le risque de déclin futur.
Nous nous proposons  donc d’analyser le rôle important
des biomarqueurs dans le développement de traitements
innovants de la MA et les dispositions réglementaires qui
s’y rapportent.
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